4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Gastroparesis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 27 ongoing clinical trials involving Gastroparesis
Of the 27 trials,15 trials are in Phase II
Furthermore, 5 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Gastroparesis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Gastroparesis, a Gastrointestinal disorder. The largest number of ongoing clinical trials for Gastroparesis is conducted in North America. Asia-Pacific and Europe are among other prominent regions engaged in Gastroparesis-related drug trials.

Gastroparesis related clinical trial sponsor

Mayo Clinic, Vanda Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are few notable clinical trial sponsors involved in Gastroparesis . A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Gastroparesis

Metoclopramide (Gimoti) and Domperidone (Nauzelin/ Motilium/ Gastractiv) are among the key marketed drugs involving Gastroparesis.

Metoclopramide (Gimoti) a para-aminobenzoic acid (PABA) derivative with gastroprokinetic and antiemetic activities. It functions via 5-Hydroxytryptamine Receptor 3 (5HT3 or 5 HT3 Receptor or HTR3) Antagonist; 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) Agonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist mechanism of action. Metoclopramide is formulated as spray for nasal route of administration. Gimoti is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide was first approved in 2020 and is marketed solely in the US by Eversana Life Science Services LLC.

Domperidone (Nauzelin/ Motilium/ Gastractiv) is a benzimidazole derivative, acts as an anti-emetic agent. It functions via D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist; D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3) Antagonist mechanism of action. Domperidone is formulated as tablets, film coated tablets, suspension, granules, dry syrup for oral route and suppositories for rectal route of administration. Domperidone was first approved in 1978 and is marketed globally including the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Janssen-Cilag Pty Ltd.